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ABSTRACT 26 
 27 
There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in 28 
human immnunodeficiency virus infected (HIV+) individuals receiving antiretroviral therapy. In a 29 
two-step intensive sampling pharmacokinetic trial, we compared area under the concentration-30 
time curve from 0 to 28 days (AUC0-28 days) of an active metabolite of amodiaquine, 31 
desethylamodiaquine, and treatment-emergent adverse events between antiretroviral therapy-32 
naive HIV+ adults and those taking nevirapine and ritonavir-boosted lopinavir-based 33 
antiretroviral therapy. In step 1, malaria uninfected adults (n=6/arm) received half the standard 34 
adult treatment regimen of artesunate-amodiaquine. In step 2, another cohort (n=25/arm) 35 
received the full regimen. In step 1, there were no safety signals and significant differences in 36 
desethylamodiaquine AUC0-28 days among participants in the ritonavir-boosted lopinavir, 37 
nevirapine and antiretroviral therapy-naive arms. In step 2, compared with the antiretroviral 38 
therapy-naive arm, participants in the ritonavir-boosted lopinavir arm had 51% lower 39 
desethylamodiaquine AUC0-28 days, (geometric mean [95% CI]; 23,822 [17,458-32506] vs 48,617 40 
[40,787-57,950] ng.hr/mL, p < 0.001). No significant differences in AUC0-28 days were observed 41 
between nevirapine and antiretroviral therapy-naïve arms. Treatment-emergent transaminitis 42 
was higher in the nevirapine (20% [5/25]) than the antiretroviral therapy naïve (0.0% [0/25]) arm 43 
(risk difference 20% [95% CI:4.3-35.7] p=0.018). Ritonavir-boosted lopinavir antiretroviral 44 
regimen was associated with reduced desethylamodiaquine exposure which may compromise 45 
artesunate-amodiaquine’s efficacy. Co-administration of nevirapine and artesunate-46 
amodiaquine may be associated with hepatoxicity.  47 
 48 
Key words: Amodiaquine; Antiretroviral therapy; Malaria  49 
 50 
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INTRODUCTION 51 
 52 
Human immunodeficiency virus (HIV) and Plasmodium falciparum (Pf) malaria infections are 53 
endemic in most regions in sub-Saharan Africa (SSA) and co-infections occur frequently. HIV 54 
infection increases susceptibility (1–3) and severity of Pf malaria (4–6), and reduces the efficacy 55 
of antimalarial drugs (7). The World Health Organisation (WHO) recommends initiation of triple 56 
antiretroviral therapy (ART) in HIV-positive (HIV+) individuals regardless of CD4 cell count (8). 57 
The recommended ART in SSA contain non-nucleoside reverse transcriptase inhibitors 58 
(NNRTIs), such as efavirenz (EFV) and nevirapine (NVP), or protease inhibitors (PIs) such as 59 
ritonavir-boosted lopinavir (LPV/r). The WHO also recommends artesunate-amodiaquine (AS-60 
AQ), as one of the first-line treatment for uncomplicated malaria (9).  61 
 62 
HIV-malaria co-infected individuals require concurrent treatment with ACTs and ART, potentially 63 
resulting in pharmacokinetic interactions (10). Drug information sheets for ACTs caution against 64 
concurrent use of ACTs and ART because NNRTIs or PIs and ACTs are metabolized by 65 
cytochrome-P (CYP) 450 liver enzymes (particularly, CYP3A4). NNRTIs such as nevirapine and 66 
efavirenz usually induce various CYP450 enzymes but are also substrates for CYP450 isoforms 67 
(CYP3A4) (11, 12). AQ is rapidly metabolised, mainly by CYP2C8 but also CYP3A4, to its 68 
metabolite, desethylamodiaquine (DESAQ), which is responsible for almost all the antimalarial 69 
effect (13, 14). This metabolite has a longer half-life and is eliminated slowly compared to AQ 70 
(13–19). Thus, co-administration of NNRTI-based ART with AS-AQ could reduce AQ and 71 
DESAQ blood concentrations resulting in lower efficacy of AQ. Conversely, HIV protease 72 
inhibitors, particularly ritonavir, are potent inhibitors of the CYP3A4 isoform. Co-administration of 73 
protease inhibitor-based ART with AS-AQ could lead to elevated AQ and lower DESAQ 74 
concentrations, potentially resulting in toxicities or reduced AS-AQ efficacy (20).  75 
 76 
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To characterize the interactions between AS-AQ and ART, we compared the pharmacokinetic 77 
parameters (AUC0-28 days, Cmax, tmax and t1/2) of the longer acting partner drug of AS-AQ, 78 
amodiaquine and of its metabolite-DESAQ, and incidence of adverse events in HIV+ adults 79 
taking AS-AQ plus NVP-ART or LPV/r-ART and those taking AS-AQ only in a parallel design 80 
(two-step) study. 81 
 82 
RESULTS 83 
Characteristics of study participants  84 
In step 1, 18 participants were successfully enrolled and followed up for 28 days, including 1 85 
subject who replaced a participant who was withdrawn following a protocol violation. In step 2, 86 
75 were enrolled and successfully followed up to 28 days, including 2 who replaced those who 87 
were lost to follow-up.  88 
 89 
Supplementary Table 1 shows baseline characteristics of participants who completed follow-up 90 
in steps 1 and 2. In both step 1 and step 2, the majority of participants in all study arms, except 91 
the step 1 ART naïve arm, were females. Participants in the LPV/r arm had a tendency towards 92 
higher alkaline phosphatase levels at baseline than those in the ART-naïve arm. In step 2, 93 
participants in the LPV/r arm had a higher median age than those in the other study arms. The 94 
median duration on ART was longer in the LPV/r than the NVP arm. All the participants in step 1 95 
and the majority (80%) in step 2 were on cotrimoxazole prophylaxis.  96 
 97 
Pharmacokinetics of AQ and DESAQ and interactions with ART in step 1 98 
PK data were available for 17 of the 18 participants who completed follow-up in step 1. The 99 
excluded participant had unquantifiable drug or metabolite concentrations at nearly all follow up 100 
time points. AQ concentrations were well below the HPLC assay limit of quantification 101 
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(LLQ=25ng/mL). Therefore, no formal comparisons of AQ PK parameters were performed 102 
across the study arms. 103 
 104 
As shown in Table 1a, the geometric mean [95% CI] of DESAQ Cmax was 60% lower in the 105 
LPV/r-ART arm (42 [34-51] ng/mL) compared to the ART-naïve arm (106 [63-179] ng/mL, 106 
p=0.006), while no significant difference in DESAQ AUC0-28 days was observed between the 107 
LPV/r-ART (4,128 [1,946- 8,758] ng.hr/mL) and the ART-naïve (7,920 [5034-12459] ng.hr/mL, 108 
p=0.10) arms. The Cmax for DESAQ were similar between participants in the NVP and ART-109 
naïve arms. Similarly, no differences in mean AUC0-28 days were observed between the NVP-ART 110 
and ART-naïve arms. As shown in the concentration-time plot in Figure 1, DESAQ 111 
concentration-time profile was notably lower in the LPV/r-ART arm compared to the ART-naïve 112 
and NVP-ART arms. There were no significant differences in half-life and Tmax of DESAQ 113 
between the NVP and ART naïve arms as well as between the LPV/r and ART naïve arms. 114 
 115 
Safety assessment in step 1 116 
After AS-AQ administration, one participant in the NVP arm developed headache and chills, 117 
which resolved without any treatment and were judged as not related to the study drug. As 118 
shown in Table 2a, treatment-emergent grade 3 or 4 neutropenia was observed in the NVP-ART 119 
arm (50% [3/6]), LPV/r-ART arm (33% [2/6]) and ART-naive arm (17% [1/6]). One participant in 120 
the AS-AQ plus NVP arm had a car accident which was not thought to be related to the study 121 
drug.  122 
 123 
Pharmacokinetics of DESAQ and interactions with ART in step 2 124 
In step 2, PK data were available for 74 of the 75 participants  who completed follow-up. The 125 
excluded participant had unquantifiable drug or metabolite concentrations at nearly all follow up 126 
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time points. Similar to our observation in step 1, AQ concentrations in step 2 were well below 127 
the HPLC assay limit of quantification (LLQ=25ng/mL).   128 
 129 
Table 1b shows that the geometric mean [95% CI] of DESAQ Cmax was 45% lower in the LPV/r-130 
ART arm (248 [199, 310] ng/mL) compared to the ART-naïve arm (448 [374, 534] ng/mL,  131 
p<0.001), while DESAQ AUC0 – 28 days was 51% lower in the LPV/r-ART arm (23,822 [17,458-132 
32,506] ng.hr/mL) compared to the ART-naïve arm (48,617 [40,787-57,950] ng.hr/mL, p<0.001) 133 
In contrast, there were no significant differences in AUC0–28 days and Cmax between the NVP-134 
treated and the ART naive arms. Also, there were no significant differences in DESAQ Tmax 135 
among the ART-naïve, LPV/r-ART and NVP-ART study arms. DESAQ half-life and clearance 136 
were significantly shorter and faster, respectively, in the LPV/r-ART arm compared with the 137 
ART-naïve arm.  138 
 139 
Figure 1 shows the concentration-time plot for DESAQ in the study arms. Similar to the findings 140 
in steps 1, DESAQ concentration-time profile in step 2 was notably lower in the LPV/r-ART arm 141 
when compared with the ARV-naïve arm. 142 
 143 
Day 7 plasma DESAQ levels by ART arm in step 2 144 
Compared with the geometric mean concentration [95% CI] of DESAQ at day 7 in the ART-145 
naïve arm (94 [73, 120] ng/ml), the concentration was 52% lower in the LPV/r arm (45 [29, 73] 146 
ng/ml, p=0.011) and was 28% lower in the NVP arm (68 [57, 80] ng/ml, p=0.092).  However, 147 
there were no significant differences in the proportion of participants with Day 7 DESAQ levels 148 
below 75ng/ml (a threshold associated with 100% parasitological cure rate (19)) between the 149 
LPV/r arm (67%, [14/21]) and the ART-naive arm (43%, [9/21], p=0.215.), and between the ART 150 
naïve arm and the NVP arm (56%, [14/25], p=0.554) 151 
 152 
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Safety assessment in step 2  153 
Overall, gastrointestinal symptoms (such as vomiting or diarrhoea) or neurological symptoms 154 
(such as headache) were not reported following intake of AS-AQ in the different study arms.  155 
However, as shown in Table 2b, there was a statistically non-significant trend towards higher 156 
incidence of grade 3 or 4 treatment emergent neutropenia in the NVP arm (28.0% [7/25] 157 
compared to ART-naïve arm (16.0% [4/25] , p=0.496). The incidence of grade 3 or 4 post-158 
dosing neutropenia was lower in the LPV/r arm (0.0% [0/25], p=0.110). The incidence of 159 
treatment-emergent grade 3 or 4 transaminitis (concurrent ALT and AST elevation) was higher 160 
in the NVP arm (20% [5/25]) than the ART naïve arm (0.0% [0/25], risk difference 20% [95% CI: 161 
4.3, 35.7] p=0.018). Similar to the ART-naïve arm, there were no cases of treatment-emergent 162 
grade 3 or 4 transaminitis in the LPV/r arm. Two cases of QTc prolongation (change in QTc 163 
>60ms from baseline to Cmax) were detected in both the LPV/r-ART arm (8.0%, n=25) and the 164 
NVP-ART am (8.0%, n=25) arms but none were detected in the ART-naïve arm (0.0%, n=25). 165 
No significant differences were found between any of the ART arms and the ART-naïve arm 166 
(p=0.490). These cases resolved spontaneously within two weeks of occurrence.  167 
 168 
DISCUSSION 169 
In this study, we found that median DESAQ AUC and Cmax were significantly lower in the 170 
LPV/r- arm when compared to the ART-naïve arm but no differences were observed in these PK 171 
parameters between the NVP and ART-naïve arms.  While AS-AQ appeared to be generally 172 
tolerated in all study arms, treatment-emergent transaminitis was more common in the NVP-arm 173 
than in the ART-naïve arm.  174 
 175 
Our findings of insignificant differences in PK parameters of DESAQ between the ART naive 176 
and NVP group are in contrast with those from a previous Nigerian open-label parallel-arm PK 177 
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study which found a lower DESAC AUC in HIV-infected adults on NVP-based ART than in ART 178 
naïve participants (21). These differences could be due to several reasons including genetic 179 
differences in CYP450 iso-enzymes of the study populations. Additional studies would be 180 
needed to explain the reasons for this discrepancy.  181 
 182 
Although highly expressed in the liver, CYP family enzymes, especially CYP3A4 and CYP2C8,  183 
are expressed in the small intenstinal epithelium and play an active role in the metabolism of 184 
drugs (22–24). Findings of significantly reduced DESAQ Cmax in the LPV/r arm at full standard 185 
dose in step 2 may partly be due to reduced CYP2C8-mediated gut or liver metabolism of AQ to 186 
DESAQ. This is plausible as CYP2C8 is the main hepatic P450 isoform that clears AQ and 187 
catalyses the formation of DESAQ (13)(25). Consequently, inhibition of CYP2C8 by its known 188 
potent inhibitors, LPV and ritonavir (10), are likely to account for the observed reduction in Cmax. 189 
Alternatively, the reduced DESAQ AUC in the LPV/r could be as a result of rapid clearance of 190 
DESAQ in the LPV/r arm compared to the ART naïve arm. However, this increased clearance is 191 
inconsistent with the known inhibitory effects of LPV/r on CYP2C8 (25). DESAQ is eliminated 192 
through extrahepatic CYP1A1 and CYP1B1 (25, 26), any potential impact that LPV/r may have 193 
on clearance of DESAQ by CYP1A1 and CYP1B1 needs to be further evaluated. 194 
 195 
Since DESAQ is responsible for nearly all the antimalarial effect of AQ (13, 14), it is likely that 196 
lower DESAQ exposure (reduced Cmax and AUC at full standard dose) in those taking LPV/r 197 
may result in lower treatment efficacy or prophylactic effect. Indeed, previous studies which 198 
administered amodiaquine base at a dosage of 10 mg/kg/day found that lower day 7 DESAQ 199 
concentrations were associated with an increased risk of treatment failure (14)(19). In the study 200 
by Strepniewska (19), patients with Day-7 DESAQ concentrations above 75 ng/mL achieved 201 
100% parasitological cure rate while 60% (n=5) of the participants who had Day-7 DESAQ 202 
concentrations of below 75 ng/mL had PCR confirmed recrudescent parasitaemia. The daily 203 
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and total amodiaquine dose received by participants in step 2 (9.5 mg/kg/day and 28.5 mg/kg, 204 
respectively) falls within the middle of WHO’s therapeutic dose range of 7.5 to 15 mg/kg/day for 205 
amodiaquine (27)(28)(14). The higher frequency of participants below the 75 ng/mL level in the 206 
LPV/r arm suggests that, in this population, the current dosage of AS-AQ may likely result in 207 
treatment failure or recurrent malaria infections. 208 
 209 
Our finding of a higher incidence of neutropenia in the NVP-ART arm than the ART naïve arm is 210 
consistent with results from a previous Ugandan study which found an increased risk of 211 
neutropenia in children receiving AQ-AS and ART (20). Although blood levels of AQ and AS 212 
were not measured in the Ugandan study, the observed cases of neutropenia could have been 213 
due to high AQ or DESAQ levels. NVP has been associated with granulocytopenia as a marker 214 
of hypersensitivity (29). Any potential synergistic role of AQ and NVP in causing neutropenia or 215 
other haematological abnormalities requires further understanding. Additionally, administration 216 
of AS-AQ in our study was associated with transient liver function abnormalities, especially in 217 
people taking NVP-based ART. This finding is similar to significant increases in liver 218 
transaminase levels observed in a previous study when AS-AQ was co-administered with an 219 
NNRTI (efavirenz) (30). NVP is independently associated with hepatotoxicity (31, 32), so is AQ 220 
(33, 34). Thus, combining these drugs may have an additive hepatotoxic effect. The observed 221 
cases of transaminitis in the NVP arm could have been due to an increase in NVP 222 
concentrations following co-administration with AQ or a result of a synergistic effect of NVP and 223 
AQ as previously experienced among individuals taking an NNRTI (efavirenz) and AQ (30). 224 
Since we did not measure NVP concentrations, we were unable to ascertain the 225 
pharmacokinetic changes in steady state concentrations of NVP after administration of AQ and 226 
the impact this may have on incidence of transaminitis. Despite the fact that haematological and 227 
hepatic abnormalities found in our study were not clinically significant and did not persist beyond 228 
two weeks, our findings suggest that caution should be exercised when co-administering AS-AQ 229 
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and NVP or the need for careful monitoring of liver function and haematological changes in 230 
malaria-infected HIV+ patients taking AS-AQ, particularly those taking AS-AQ plus NVP.  231 
 232 
The present study was not adequately powered to detect adverse events such as cardiac 233 
toxicity. In our study, AQ levels were below the HPLC assay limit of quantification possibly due 234 
to lack of sensitivity of the assay in detecting very low plasma drug concentrations. Although this 235 
study was not aimed at examining dose proportionality between the two steps, the inability to 236 
observe this and to detect significant differences in PK parameters across arms and between 237 
steps may have been due to a very small sample size in step 1 relative to step 2 and the use of 238 
the parallel-arm design, which is more prone to effects of inter-individual anthropometric and 239 
genetic variations than a cross-over design. Genetic polymorphisms in CYP 450 iso-enzymes 240 
may have contributed to wide interquartile ranges of DESAQ PK parameters observed within 241 
each study arm. However, our study sample size is unlikely to have missed large (>2-fold) 242 
clinically important differences in AUC across the study arms. Future studies should explore 243 
dose linearity when AS-AQ is administered with antiretroviral drugs, assess the effect of genetic 244 
polymorphisms on the pharmacokinetics of DESAQ, quantify any changes in plasma ART levels 245 
when co-administered with antimalarial drugs and explore any potential impact of artesunate on 246 
the metabolism of amodiaquine when co-administered with antiretroviral drugs. 247 
 248 
In conclusion, this study found significant PK interactions between LPV/r and AS-AQ, and 249 
signals of transaminitis and neutropenic effects among those taking NVP and AS-AQ. The 250 
clinical therapeutic implications of these findings in malaria-infected individuals on ART need 251 
further evaluation. 252 
 253 
 254 
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MATERIALS AND METHODS 255 
Study Design 256 
We conducted an open-label, parallel arm, pharmacokinetic (PK) trial at Queen Elizabeth 257 
Central Hospital, Malawi, from August 2010 to March 2013. The study was implemented in two 258 
steps;  259 
 260 
1. In step 1 (N=18) [PACTR2010030001871293], we administered half adult oral doses 261 
of AS-AQ (1 tablet of Coarsucam™, Sanofi-Aventis containing AS/AQ 100mg/270mg) at 262 
0, 24 and 48 hours, to HIV+ malaria-negative individuals in the following arms: (i) those 263 
on NVP-d4T-3TC, (ii) those on AZT-3TC-TDF-LPV/r and (ii) antiretroviral naive 264 
individuals which served as a control arm. step 1 served as a safety evaluation step, 265 
checking for unexpected clinical toxicities or interactions.  266 
 267 
2. In step 2 (N=75) of the study [PACTR2010030001971409], after review of step 1 268 
safety data by an independent Data Safety Monitoring Board (DSMB), full treatment 269 
doses of AS-AQ (2 tablets of Coarsucam™, Sanofi-Aventis, each containing AS/AQ 270 
100mg/270mg) were administered to additional HIV+ individuals in the same arms and 271 
at the same time intervals as in step 1.  272 
 273 
All doses of AS-AQ were administered with water only as recommended by Sanofi-Aventis.  274 
 275 
Study Population  276 
The target population for both steps were HIV+ male and non-pregnant female adults aged ≥18 277 
years residing in Blantyre or neighbouring districts of Thyolo and Chiradzulu. Individuals were 278 
eligible if they had been on NVP-ART or LPV/r-ART for ≥ 6 months and had CD4 cell count ≥ 279 
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250 cells/mm3. At the beginning of the study, HIV+ antiretroviral naive individuals were eligible 280 
for recruitment into the study if they had a CD4 cell count ≥ 250/mm3 but this cut-off point was 281 
increased to ≥350/mm3 when the new WHO criteria for ART initiation was implemented in 282 
Malawi in July 2011 (35). Other inclusion criteria were body weight ≥40kgs, willingness to be 283 
admitted in the hospital for 3 days, to remain within the study sites and be contacted by phone 284 
or at home during the course of the study.  285 
 286 
We excluded subjects who met any of the following criteria:  287 
i. Body Mass Index ≤18.5kg/m2  288 
ii. Haemoglobin concentration <8.5 g/dL  289 
iii. Reported use of any antimalarial drugs within the preceding 4 weeks  290 
iv. Reported hypersensitivity to any of the ACTs  291 
v. Receipt of other drugs which are known inhibitors or inducers of P450 enzymes or P-292 
glycoprotein (except cotrimoxazole prophylaxis)  293 
vi. History of regular intake of alcohol (>twice/week), tobacco (>3 times/week) or use of 294 
illicit drugs  295 
vii. History or evidence of pre-existing liver, kidney or heart disease, including conductive 296 
abnormalities on electrocardiographs (QTc interval>450ms in men, >470ms in females)  297 
viii. Clinical and/or laboratory evidence of Pf malaria, hepatitis B, pneumonia, tuberculosis, 298 
bacteraemia or laboratory evidence of potentially life threatening disorders 299 
ix. Karnofsky score of <80% 300 
 301 
Sample size: 302 
The sample size in step 1 was 6 for each of the three arms. This approach was based on 303 
standard practice in early PK studies of antimalarial drugs which aim to safeguard the safety of 304 
study subjects and minimize the number of subjects who may be potentially exposed to harmful 305 
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drug levels. The sample size for step 2 was 25 per arm which gave at least 90% power to detect 306 
a two-fold increase in the DESAQ AUC in any of the AS-AQ plus ART arms, assuming a mean 307 
DESAQ AUC of 154 ng/ml/hr (standard deviation of 150 ng/ml/hr (2)) in the AS-AQ control arm, 308 
at the 5% significance level. 309 
 310 
Ethics 311 
The study conformed to the principles of the International Conference on Harmonization on 312 
Good Clinical Practice and was approved by the College of Medicine Research Ethics 313 
Committee (COMREC) in Malawi. Written informed consent, to participate in the study, was 314 
sought from potential participants. 315 
 316 
Screening and enrolment 317 
Research nurses and clinicians sought written informed consent from individuals to perform 318 
screening procedures including physical medical and anthropometric assessment, 319 
electrocardiographs (ECGs) and blood tests to detect blood-borne infections, haematological, 320 
renal or hepatic abnormalities. Based on the results from screening procedures which were 321 
available within 7 days, potential study participants were informed about their eligibility to 322 
participate in the study. Consenting study participants were re-assessed by research nurses or 323 
clinicians to determine whether they still met all eligibility criteria, through repeat history taking 324 
and physical examination. Eligible participants were admitted in hospital and an indwelling 325 
cannula was inserted into a vein before their scheduled dose of ART and the first dose of the 326 
ACT. Approximately 1 hour before the scheduled time of ART and ACT dosing, blood samples 327 
were collected for haematological, renal and liver function tests and also random glucose test. 328 
 o
n
 M
ay 17, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://aac.asm
.org/
D
ow
nloaded from
 
Amodiaquine and antiretroviral therapy 
14 
 
 329 
Blood sample collection and follow-up procedures 330 
While participants were hospitalized, blood samples for PK assays were collected in heparin 331 
vacutainer tubes, pre-treatment and at the following post-treatment times: 0, 0.25, 0.5, 1, 1.5, 2, 332 
3, 4, 5, 6, 8, 12, 24, 36, 48, 60 and 72hours. After discharge from hospital, blood samples were 333 
taken at 4, 5, 6, 7, 14, 21 and 28 days. Immediately after collection, samples were spun in a 334 
refrigerated centrifuge and the separated plasma was temporarily frozen in liquid nitrogen 335 
before being transferred to a -80˚C freezer until PK analyses.  336 
 337 
Participants were monitored for 28 days after administration of the first study dose to detect 338 
clinical adverse events. Blood samples to detect haematological, renal and liver function 339 
abnormalities were collected at 12, 48 and 72 hours and days 7, 14, 21 and 28. Participants 340 
were monitored for treatment emergent adverse events (AEs), defined as any clinical or 341 
subclinical abnormality which was absent before dosing with AS-AQ but emerged post dosing, 342 
or a clinical or subclinical abnormality which was present before dosing with AS-AQ but 343 
worsened post-dosing. Severity of AEs was graded using the DAIDS criteria (36). In addition, 344 
12-lead ECGs were performed pre-dosing, 2 hours after the first dose and 2 hours after the last 345 
dose in step 2 to assess Fridericia-corrected(37) QT interval. 346 
 347 
Pharmacokinetic assays  348 
Plasma samples were analysed for AQ and DESAQ levels using a validated HPLC-UV assay 349 
adopted and transferred to Malawi-Liverpool Wellcome Trust Clinical Research Programme in 350 
Blantyre, Malawi from Liverpool School of Tropical Medicine. The PK laboratory in Blantyre 351 
participated in WWARN’s External Quality Assurance programme(38). Briefly, AQ/DESAQ and 352 
the internal standard (Quinidine) were recovered from plasma using liquid extraction (diethyl/tert-353 
butyl ether). The supernatant was evaporated to dryness in a vacuum concentrator at 25 0C. The 354 
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residue was re-dissolved in 200 µl of the reconstitution mobile phase: Water–Acetonitrile–355 
Triethylamine (85:15:1, v/v/v; pH 3) and 75 µL was injected into the chromatograph (Agilent 356 
1100). The optimum detection wavelength for each drug was 345 nm. The lower limit of 357 
quantification (LLOQ) of the HPLC-UV assay was 25 ng/mL for the drugs AQ/DESAQ. Extracted 358 
plasma PK samples were run in batches. Each batch run included a blank plasma extract, two 359 
sets of 8-concentration-level calibration standards, and quality controls (QC) at three 360 
concentration levels: low, medium and high (0.025, 1500 and 3000 ng/mL for AQ/DESAQ). For 361 
batch assay to pass the measured concentrations, at least 67% of the QC samples had to be 362 
within +/-20% of their nominal value and at least one QC had to be acceptable at the LLOQ. In 363 
addition, 75% of each calibration curve's concentrations had to lie within +/-20% and +/-15% of 364 
the nominal concentration at the LLOQ or all other concentrations, respectively. The mean 365 
interassay precision for low, medium and high QCs was 15%, 9% and 6% respectively.  366 
 367 
Data analyses  368 
Plasma concentrations of AQ/DESAQ were analysed using non-compartmental 369 
pharmacokinetic analysis (NCA), employing  the trapezoidal rule with cubic splines. Observed 370 
AQ/DESAQ concentrations below LLOQ were treated as missing data except for the pre-dose 371 
concentration which was imputed to 0 if below LLOQ. For each study participant, the following 372 
PK parameters were computed: AUC0-28 days, maximum concentration [Cmax], time to maximum 373 
concentration [tmax] and terminal elimination half-life [t1/2]). We used STATA 15.0 for the NCA 374 
and to compare PK parameters. The Two-sample Wilcoxon rank-sum (Mann-Whitney-U test) 375 
was used to test any significant differences in PK parameters between each ACT/ART arm and 376 
the control arm (α=0.05). Geometric means and their 95% confidence intervals have been 377 
reported. Fisher’s exact test was used to compare proportions of participants across the study 378 
groups with day 7 concentrations that were above a value known to predict treatment response 379 
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by day 28, and of safety parameters across the different ACT/ART groups in comparison to the 380 
ART naïve group. Data summaries and graphics were all performed in STATA 15.0.  381 
 382 
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LEGEND 562 
Figure 1: Desethylamodiaquine concentration-time profile (semi-log scale) in step 1 (left; n=17) 563 
and step 2 (right; n=74) following oral administration of half and full standard artesunate-564 
amodiaquine adult treatment courses, respectively, among HIV infected ART naïve (blue), those 565 
on nevirapine- (red) and ritonavir-boosted lopinavir-based (green) antiretroviral therapy. Below 566 
limit of quantification concentrations are not included (resulting in observation time up to 144 567 
hours in step 1 and 504 hours in step 2). Data are presented as mean (95% confidence interval) 568 
 569 
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       Table 1a: Desethylamodiaquine pharmacokinetic parameters for participants in step 1 
   
 
Study groups Geometric Mean Ratio (p-value) 
  ART naïve                      
n=5* 
NVP                                 
n=6 
LPV/r                          
n=6 
NVP/ART naïve LPV/r/ART naïve 
AUC0-28 days, hr.ng/mL 7,920 (5,034-12,459) 6,091 (3,096-11,983) 4,128 (1,946-8,758) 0.77 (0.465) 0.52 (0.100) 
Cmax (ng/mL) 106 (63-179)  75 (54-105) 42 (34-51)  0.71 (0.273) 0.40 (0.006) 
Tmax (hr) 60 (36-60) 60 (3-60) 60 (36-60) (0.562)
a
 (0.484)
a
 
t1/2 (hr) 59 (9-381) 88 (23-331) 75 (16-334) 1.49 (0.715) 1.27 (0.715) 
PK parameters are presented as geometric mean (95% confidence interval) except for Tmax, which is reported as median (range). P-value for the ratio is calculated using 
Wilcoxon rank sum test in Stata 15.0 
 ART=antiretroviral therapy; NVP=Nevirapine-based ART; Cmax=maximal concentration, Tmax=time to reach maximal concentration, t1/2=drug elimination half-life. 
 AUC0-28 days =area under concentration-time curve from 0 hours 
to 28 days 
 
   
* One participant did not have quantifiable DESAQ concentrations at nearly all follow up time points and was 
excluded from analysis 
a: p-value only, calculated using Wilcoxon rank sum test 
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 Table 1b: Desethylamodiaquine pharmacokinetic parameters for 
participants in step 2 
     Study groups Geometric Mean Ratio (p-value) 
  ART naïve              
  n=25 
NVP                           
n=25 
LPV/r                        
n=24* 
NVP/ART naïve LPV/r/ART naïve 
AUC0-28 days, hr.ng/mL 48,617 (40787- 57,950) 43016 (38,300-48,313) 23,822 (17,458-32,506) 0.88 (0.308) 0.49 (0.0005) 
Cmax (ng/mL) 448 (374-534) 360 (322-403) 248 (199-310) 0.80 (0.067) 0.55 (0.0003) 
Tmax (hr) 60 (1.5-96) 60 (3-60) 60 (2-72) (0.887)
a
 (0.248)
a
 
t1/2 (hr) 166 (121-227)  234 (201-272) 90 (58-140) 1.41 (0.037) 0.54 (0.023) 
PK parameters are presented as geometric mean (95% confidence interval) except Tmax, which is reported as median (range). P-value for the ratio is calculated using Wilcoxon rank 
sum test in Stata 15.0; =0.05 
 ART=antiretroviral therapy; NVP=Nevirapine-based ART; LPV/r=ritonavir-boosted Lopinavir-based ART; Cmax=maximal concentration, Tmax=time to reach maximal concentration, 
t1/2=drug elimination half -life. 
 AUC0-28 days =area under concentration-time curve from 0 hours to 28 days 
 
   
* One participant did not have quantifiable DESAQ concentrations at nearly all follow up time points and was excluded 
from analysis 
a: p-value only compared using Wilcoxon rank sum test 
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Table 2a: Summary of DAIDS Grade 3 or 4 Treatment-emergent adverse events in Step 1 
DAIDS (Grade 3 or 4) Treatment-emergent 
abnormalities 
AS-AQ (Without 
ART) 
N=6 
 
AS-AQ +NVP  
N=6 
 
AS-AQ +LPV/r  
N=6 
 
n (%) n (%) n (%) 
Haematological events 
Anaemia 0 (0) 1 (17) 0 (0) 
Leucopenia 0 (0) 0 (0) 0 (0) 
Lymphopenia 0 (0) 0 (0) 0 (0) 
Neutropenia 1 (17) 3 (50) 2 (33) 
Thrombocytopenia 0 (0) 0 (0) 1 (17) 
Biochemical events 
Elevated ALT and AST 0 (0) 0 (0) 0 (0) 
Raised Creatinine 0 (0) 0 (0) 0 (0) 
Cardiac events 
QTc prolongation NA NA NA 
NA: ECG assessment not conducted in step 1 
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Table 2b: Treatment-emergent DAIDS Grade 3/4 abnormalities in Step 2 
DAIDS (Grade 3 or 4) Treatment-emergent 
abnormalities 
AS-AQ (Without 
ART) 
N=25 
 
AS-AQ +NVP  
N=25  
 
AS-AQ +LPV/r  
N=25 
 
n (%)  n (%) n (%) 
Haematological events 
Anaemia 1 (4) 0 (0) 0 (0) 
Leucopenia 0 (0) 0 (0) 0 (0) 
Lymphopenia 1 (4) 1 (4) 0 (0) 
Neutropenia 4 (16) 7 (28) 0 (0) 
Thrombocytopenia 0 (0) 2 (8) 0 (0) 
Biochemical events 
Elevated ALT and AST 0 (0) 5 (20) 0 (0) 
Raised Creatinine 0 (0) 0 (0) 0 (0) 
Cardiac events 
QTc prolongation 0 (0) 2 (8) 2 (8) 
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